Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Grant of Manufacturing...

    Grant of Manufacturing License for Drugs: DTAB recommends amendment of Drugs and Cosmetics Rules, 1945

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-29T16:10:12+05:30  |  Updated On 17 Aug 2021 11:38 AM IST

    New Delhi: The Drugs Technical Advisory Board (DTAB) has recently recommended for amendment of the Drugs and Cosmetics Rules, 1945 regarding submission of documents to get approval for manufacturing license for drugs.


    The board further recommended issuing appropriate guidelines for the applicability of provisions for modified release dosage forms, products involving complex or special manufacturing technology.


    DTAB was apprised that, the Drugs and Cosmetics Rules, 1945 have been amended mandating the submission of BA/BE studies for grant of manufacturing licence. As per the GSR 327(E), the applicant shall submit the result of bioequivalence study along with the application for grant of manufacturing licence of an oral dosage form of drugs falling under the Category II and Category IV of the Biopharmaceutical Classification System.


    The Rules have also been amended making it mandatory to submit evidence of stability, safety of excipients, etc. to State Licensing Authority along with application before grant of product manufacturing licences.


    In this context, DCC in its 56th meeting deliberated the concept of the "Dossier Approval" in respect of formulation development data, including stability data and BA/BE data, generated under the valid licence under the Drugs and Cosmetics Rules, 1945.


    It was deliberated that any person/ institution can develop a drug formulation and can generate dossier of the product development containing detailed data on formulation development, BA/BE study data, stability data, excipients compatibility, etc, and submit to the licensing authority for approval. Once such dossier is approved by licensing authority under Drugs and Cosmetics Rules, 1945, the same may be submitted by a manufacturer under an agreement for technology transfer etc. between the person/institution who has developed the formulation and the manufacturer for seeking grant of manufacturing licence for the same product subject to submission of following:




    • Equivalency report showing the similarity of raw materials, API and excipient source and specifications, packaging materials specifications, SOPs, testing methods, manufacturing and packaging processes, equipment design and principle, batch size and finished product specifications between manufacturers product and the product developed by the person/institution.

    • Comparative evaluation data including multimedia comparative dissolution profile to show the similarity between the two products.

    • Six months accelerated and long term stability data for the drug formulation generated at the applicants manufacturing site.


    Accordingly, Drugs and Cosmetics Rules may be amended to make necessary provisions in this regard, states the committee report.


    DTAB deliberated the issue and recommended for amendment of the Drugs and Cosmetics Rules, 1945 regarding dossier of approval and submission of the same for grant of manufacturing license for drugs. Further, DTAB opined that in such cases the technology followed at manufacturing site must be same as that approved through dossier approval.


    The Board also recommended that appropriate guidelines shall be issued for the applicability of these provisions for modified release dosage forms, products involving complex or special manufacturing technology.

    active pharmaceutical ingredientsAPIBABEbioequivalence studyCDSCOCDSCO committeeDossier Approvaldrug licensedrug manufacturing licenseDrugs and Cosmetics ActDrugs and Cosmetics RulesDrugs Technical Advisory BoardDTABDTAB mettingmanufacturig licenseoral dosagepharmapharma newspharma news india

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok